The scoping review analyses the impact of European Union (EU) laws, regulations, and policies on medicine access in non-EU low- and middle-income countries (LMICs) from 1995 to 2021. It identifies three key ways the EU influences pharmaceutical access in LMICs: through explicit agreements between EU-LMICs (ex. accession, trade, and economic agreements); LMICs' reliance on EU internal regulation, standards, or methods (ex. market authorisation); ‘soft’ forms of EU influence (ex. research funding, capacity building). The study emphasizes the need for global equitable access principles to guide EU-policy in this area due to the fragmented nature of EU-actions in the pharmaceutical field.